New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 26, 2012
10:00 EDTALKS, MDCO, BCEI, DKS, VAR, CBRL, ARIA, ARQLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) initiated with a Buy at Citigroup... Alkermes (ALKS) initiated with a Buy at Citigroup... ArQule (ARQL) initiated with a Buy at Citigroup... Bonanza Creek Energy (BCEI) initiated with a Buy at SunTrust... Dick's Sporting (DKS) initiated with a Market Perform at BMO Capital... The Medicines Co. (MDCO) initiated with a Neutral at Citigroup... Varian Medical (VAR) initiated with a Buy at Brean Capital... Cracker Barrel (CBRL) initiated with a Buy at CL King.
News For ARIA;ARQL;ALKS;MDCO;BCEI;DKS;VAR;CBRL From The Last 14 Days
Check below for free stories on ARIA;ARQL;ALKS;MDCO;BCEI;DKS;VAR;CBRL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 19, 2014
07:31 EDTDKSDick's Sporting reports Q2 SSS up 3.2%
07:31 EDTDKSDick's Sporting reports Q2 non-GAAP EPS 67c, cosnenssu 65c
Subscribe for More Information
07:18 EDTBCEIEnerCom to hold a conference
Subscribe for More Information
August 18, 2014
15:36 EDTDKSDick's Sporting September 43 straddle priced for 8.9% move into Q2
Subscribe for More Information
15:35 EDTDKSDick's Sporting technical comments before earnings
Subscribe for More Information
15:26 EDTDKSNotable companies reporting before tomorrow's open
Subscribe for More Information
11:41 EDTALKSCubist rises after report sparks takeover interest speculation
Subscribe for More Information
08:31 EDTVARVarian Medical board authorizes repurchase of 6M shares through 2015
Subscribe for More Information
August 15, 2014
17:07 EDTARQLBiotechnology Value Fund reports 6.9% passive stake in ArQule
Subscribe for More Information
August 13, 2014
07:58 EDTDKSDick's Sporting weakness overdone, says UBS
UBS said the weakness in Dick's Sporting Goods due to concerns about its gold segment are overdone and that the stock is likely poised for a rebound. The firm believes upcoming Q2 results will be better than feared, as foot and apparel trends remain strong, global soccer events should have a positive contribution, and promotional activity is clearing out inventory. The firm has a Buy rating and $53 price target on Dick's shares.
August 12, 2014
08:03 EDTDKSGoldman's Retail selections for Q2
Goldman is most above Q2 consensus for Advance Auto Parts (AAP), Best Buy (BBY) and Williams-Sonoma (WSM), sees best risk/reward in Ulta Salon (ULTA) and Sportsman's Warehouse (SPWH), and low visibility in Dick's Sporting (DKS) and Wal-Mart (WMT).
August 11, 2014
06:52 EDTDKSDick's Sporting still has a downward bias to estimates, says RBC Capital
Subscribe for More Information
August 8, 2014
12:12 EDTDKSDick's Sporting volatility elevated into Q2 and outlook
Subscribe for More Information
10:36 EDTDKSOptions with increasing implied volatility
Subscribe for More Information
10:16 EDTDKSHigh option volume stocks
High option volume stocks: TKMR JOE HMSY TDC XOMA XPO VGK DKS BCOR DRTX
August 7, 2014
17:56 EDTMDCOThe Medicines Co. could have 25% upside, Barron's says
FDA approval of The Medicines Co. skin infection drug Orbactiv should give shares a boost and although the stock is not cheap, it is cheap enough to buy, Barron's argues in its Barron's Take column. The company's pipeline should bolster its earnings, the paper adds. Reference Link
16:51 EDTBCEIBonanza Creek sees FY14 average production 23,200-25,200 Boe/d
Subscribe for More Information
16:49 EDTBCEIBonanza Creek reports Q2 adjusted EPS 52c, consensus 68c
Subscribe for More Information
08:12 EDTMDCOThe Medicines Co. to host conference call
Subscribe for More Information
05:11 EDTMDCOThe Medicines Co. Orbactiv approved by FDA
The Medicines Company announced that the FDA has approved Orbactiv for injection for the treatment of adults with acute bacterial skin and skin structure infections, or ABSSSI, caused by susceptible designated Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. Orbactiv is the first and only antibiotic approved by FDA to treat ABSSSIs with a single, once-only administration. Once fully infused over three hours, the Orbactiv treatment regimen is complete for patients with skin infections caused by susceptible Gram-positive pathogens.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use